Medical Device and Healthcare Trends — 2026-05-21

Top 5 Headlines

• FDA rejects proposals to ease oversight for low-risk AI devices and wearables, reaffirming patient safety and clinical validation as top priorities.
• Samsung unveils a connected home-based AI healthcare platform, linking wearables, home appliances, and AI to create a remote patient-provider ecosystem.
• Global Medtech Market approaches USD 945.7 billion driven by AI and digital health; expected to exceed USD 1 trillion by 2032.
• FDA 2026 Guidelines clarify entry requirements for AI-embedded medical devices and wearable biosensors; maintaining strict rules for high-risk devices while selectively easing for low-risk.
• Lunit expands U.S. subscription-based AI business, surpassing 930,000 cumulative SaaS contracts, raising potential in the global digital pathology M&A market.

Key Corporate Developments

Samsung — Unveils Connected Home Healthcare Platform Strategy

• What Happened: Samsung Business Insights announced a home healthcare platform strategy utilizing AI and everyday devices. It suggests a blueprint for an ecosystem where wearables, smart TVs, and refrigerators act as health data hubs, remotely connecting patients and medical staff.
• Numbers: Specific revenue figures were not disclosed, but the global connected home healthcare market has been set as a core growth pillar.
• Implications: This marks a strategic shift where Samsung’s consumer electronics branch expands into a medical platform. Synergy with Samsung Medison could secure a unique competitive edge in remote monitoring. Success hinges on regulatory changes in domestic remote medical care discussions.

Lunit — Hits 930,000 U.S. SaaS Contracts, Partners with Severance Hospital

• What Happened: Lunit surpassed 930,000 cumulative contracts for its SaaS-based AI solutions in the U.S. and signed an MOU with Severance Hospital for joint development and clinical application of medical AI foundation models.
• Numbers: Over 930,000 cumulative U.S. SaaS contracts; holds significant upside potential in the global digital pathology M&A market.
• Implications: As M&A activity in global digital pathology heats up, Lunit’s expanding U.S. subscription model increases its appeal as a partner or acquisition target. The collaboration with Severance Hospital will strengthen its domestic clinical data base and accelerate the refinement of its foundation models.

Classys — Q1 Operating Profit Margin Hits 42.7% Following Acquisition of Brazilian Distributor

• What Happened: Classys announced its 2026 Q1 earnings, bolstered by the integration of Brazilian distributor MedSystems. Operating profit saw a slight decline due to one-time accounting treatments.
• Numbers: Q1 revenue of KRW 87.2 billion (+13% YoY), operating profit margin of 42.7%; operating profit down 4.1% YoY due to one-time factors.
• Implications: This case demonstrates that internalizing direct distribution is effective for defending mid-to-long-term profitability. The early-mover advantage in emerging aesthetic medical device markets like Brazil is beginning to reflect in performance, serving as a benchmark for other domestic companies.

Global Medtech Market — Nears USD 945.7 Billion Driven by AI and Digital Health

• What Happened: According to a recent QYResearch report, AI, digital health, and minimally invasive platforms are driving the global medical device market, which is expected to surpass USD 1 trillion by 2032.
• Numbers: Current market size is approximately USD 945.76 billion, including CAGR estimates from 2026 to 2032.
• Implications: With surging global demand for AI medical devices and minimally invasive tools, Korean companies have opportunities to expand global market share in niche fields like aesthetic devices, AI diagnostic imaging, and digital therapeutics. Regulatory trends from the FDA and the Ministry of Food and Drug Safety (MFDS) remain key variables determining entry speed.

MFDS · Policy · Regulation

Abolition of 'Suspension Grace Period' for GMP Violations

• Content: The grace period previously applied to sales suspensions when receiving a "supplementary" rating during regular GMP (Good Manufacturing Practice) audits has effectively ended. For in-vitro diagnostic devices, only a limited 30-day grace period from the date of the audit result is granted.
• Targets: Manufacturers and importers of medical and in-vitro diagnostic devices.
• Effective Date: Applied since the March 2026 notice.
• Industry Impact: The importance of managing GMP validity and responding to regular audits has increased. Companies must operate stricter compliance systems, as receiving a "supplementary" rating now triggers immediate sales suspension risks. Compliance burdens on small and medium-sized manufacturers are expected to rise.

Government Supply System for Rare Disease Devices and AI False Advertising Ban Bill Passed

• Content: The MFDS passed an amendment to the Medical Device Act, establishing a government-led supply system for rare disease medical devices. It also explicitly includes clauses banning AI-generated false expert advertisements.
• Targets: Manufacturers/importers of rare disease medical devices and companies involved in AI-based medical/healthcare marketing.
• Effective Date: Amendment passed on May 8, 2026.
• Industry Impact: A new business model opens for companies entering the rare disease market, with the government acting as a buyer and supply channel. The ban on AI-generated false ads requires companies using digital marketing to strengthen their ad review processes.

Clarification of Medical Device Classification Criteria — 'Dalcon Shield' Case Revisited

• Content: The MFDS is refining criteria for determining whether a product qualifies as a medical device and its classification. The process is now clarified to require the submission of three types of documents (intended use, design/structure/material/performance/method, and principle of operation/standards) to the Minister of Food and Drug Safety for formal review.
• Targets: Companies developing new products where medical device status is unclear, and companies in boundary areas (e.g., healthcare IoT, wellness devices).
• Effective Date: Applied since the February 2026 notice.
• Industry Impact: Practical standards for digital healthcare startups and wellness device manufacturers have been strengthened, requiring pre-classification confirmation before product launch. This is expected to reduce the risk of post-market sanctions caused by misclassification.

Digital Health · AI Healthcare

• FDA AI Medical Device 2026 Guidelines: The FDA announced 2026 guidance for AI-embedded medical devices and wearable biosensors, aiming to maintain regulation for high-risk devices while differentiating oversight for some low-risk wellness functions. However, the recent rejection of proposals to ease oversight for low-risk AI medical devices reaffirms the importance of clinical validation.

• Lunit × Severance Hospital: Lunit signed an MOU with Severance Hospital for joint development and clinical application of medical AI foundation models. Expanding technical scope from traditional AI diagnostic imaging to multimodal foundation models, they are securing strongholds in major domestic hospitals.

• Samsung Connected Home Care Platform: Samsung announced its home healthcare platform strategy, connecting everyday devices like the Galaxy Watch and smart appliances as hubs for medical data collection and transmission. It aims to provide continuous pre- and post-hospitalization care services with AI-based patient monitoring.

Global Medtech Context

• FDA Rejects AI Medical Device Oversight Easing — Denied requests to ease regulations on low-risk AI devices, citing patient safety and clinical validation. Implications for Korea: Strengthening clinical evidence has become an essential element for AI firms like Lunit and Vuno in their FDA approval strategies.

• Global Medtech Market Nears USD 945.7 Billion, Driven by AI and Minimally Invasive Growth — A USD 1 trillion market is expected by 2032. Implications for Korea: A "golden time" for Korean firms in diagnostic AI, aesthetic devices, and minimally invasive robotic surgery to expand global market share.

• FDA Releases Guidance on Exempting Some AI Software and Wearable Features (January 2026) — Clarified non-regulatory scope for low-risk wellness functions and clinical decision support tools. Implications for Korea: Established criteria that electronics companies like Samsung and LG can use to identify regulatory boundaries when entering the U.S. market.

Investment · M&A · IPO Trends

• Classys — Acquisition of Brazilian Distributor MedSystems: Following integration, achieved Q1 revenue of KRW 87.2 billion (+13% YoY), pursuing a direct distribution internalization strategy. Acquisition price not disclosed.

• Lunit — Potential Beneficiary of Global Digital Pathology M&A: Cumulative U.S. SaaS contracts surpassing 930,000 build valuation factors in the M&A market. Securities firms suggest upside potential amidst the wave of global M&A in digital pathology.

Today's Insight

With the FDA's rejection of proposals to ease oversight on AI medical devices, the global regulatory stance is firmly moving toward "strengthened verification over relaxation." This directly impacts FDA approval strategies for Korean AI firms like Lunit and Vuno, suggesting that entry into the U.S. market will become increasingly difficult without accumulated clinical evidence. Meanwhile, Samsung’s focus on connected home healthcare platforms and Lunit’s collaboration on foundation models demonstrate that Korean healthcare is evolving from simple device exports into a "platform- and data-driven ecosystem." Coupled with domestic regulatory tightening from the MFDS, companies face the dual task of raising compliance levels both at home and abroad.

Checkpoints This Week

• Lunit × Severance Hospital MOU: Confirm if a roadmap for joint medical AI foundation model development and a schedule for clinical application will be announced.
• MFDS Rare Disease Device Supply System: Monitor the expected date for the announcement of detailed enforcement decrees and target product lists.
• FDA 2026 AI Guidelines: Check if domestic export companies need to adjust their approval strategies following the final version of the FDA’s AI medical device guidelines.

Action Items for Readers

• Medical Device Manufacturers/Importers: Audit GMP schedules and response processes for "supplementary" ratings, and check how the "30-day sales suspension grace period" affects your product timelines.
• AI Medical Device Startups/Investors: Review the original FDA decision document rejecting the easing of AI medical device oversight and re-examine clinical data collection plans for U.S. market entry.
• Healthcare Platform/Digital Health Companies: Reference Samsung's connected home healthcare strategy to assess whether your product or service has opportunities for B2B partnerships or platform integration.